Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations

Celia L Gregson, Ken E S Poole, Eugene V McCloskey, Emma L Duncan, Jörn Rittweger, William D Fraser, George Davey Smith, Jonathan H Tobias

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. Objective: To determine circulating sclerostin concentrations in HBM. Design: Case-control study Participants: 406 HBM index cases were identified by screening DXA databases from 4 UK centers (n=219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected relatives & spouses. Main measure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and tibial pQCT (subgroup only). Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both p
Original languageEnglish
Pages (from-to)2897–2907
JournalThe Journal of Clinical Endocrinology and Metabolism
Issue number8
Publication statusPublished - 25 Feb 2014

Cite this